title: A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
abstract: OBJECTIVE
  To compare efficacy of remaining on duloxetine 60 mg to increasing to 120 mg q.d. in patients without remission of major depressive disorder (MDD) after 6 weeks at 60 mg.
  
  
  METHODS
  This double-blind, parallel study was conducted in adults with MDD (DSM-IV-TR criteria). Patients initially randomly assigned to duloxetine 60 mg for 6 weeks with a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score > 7 (nonremitters) were randomly reassigned to 60 mg or 120 mg duloxetine for 8 weeks. Patients with a HAM-D-17 score < or =7 (remitters) continued on duloxetine 60 mg. The primary objective was to compare time to remission (HAM-D-17 score < or =7) between rerandomized groups. Secondary objectives included evaluation of HAM-D-17 and Inventory of Depressive Symptomatology assessments and safety and tolerability evaluations in nonremitters and remitters. Patients were enrolled from November 2004 to January 2006.
  
  
  RESULTS
  Nonremitters randomly reassigned to 60 mg and 120 mg achieved similar time to remission and similar improvements on efficacy measures. Remission was achieved in 30.0% and 30.5% in the 60-mg and 120-mg groups, respectively. Of the remitters, 85.5% continued to be in remission at study end. Other than a greater incidence of hyperhidrosis and chest pain in the 120-mg group, adverse events were similar between groups, as were discontinuations due to adverse events.
  
  
  CONCLUSIONS
  Nonremitters to 60 mg of duloxetine for 6 weeks randomly reassigned to 60 mg or 120 mg of duloxetine demonstrated continued symptom improvement in the 8-week extension. Patients randomly reassigned to 120 mg showed no advantage over those who continued on 60 mg. Duloxetine was well tolerated at both doses and had similar safety profiles.
authors.affiliation: Virginia Commonwealth University Mood Disorders Institute, Richmond, USA.
authors.forename: Susan G
authors.initials: SG
authors.lastname: Kornstein
authors.forename: David L
authors.initials: DL
authors.lastname: Dunner
authors.forename: Adam L
authors.initials: AL
authors.lastname: Meyers
authors.forename: Virgil G
authors.initials: VG
authors.lastname: Whitmyer
authors.forename: Craig H
authors.initials: CH
authors.lastname: Mallinckrodt
authors.forename: Madelaine M
authors.initials: MM
authors.lastname: Wohlreich
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Detke
authors.forename: Millie S
authors.initials: MS
authors.lastname: Hollandbeck
authors.forename: John H
authors.initials: JH
authors.lastname: Greist
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000068736:Duloxetine Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010555:Personality Inventory / Q000706:statistics & numerical data; D011446:Prospective Studies; D011594:Psychometrics; D019233:Retreatment; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride